Impact of Blockade of Histamine H2 Receptors on Chronic Heart Failure Revealed by Retrospective and Prospective Randomized Studies

Journal of the American College of Cardiology

Volumn 48, Issue 7, 2006, Pages 1378-1384

  Kim, Jiyoong ^a   Ogai, Akiko ^a   Nakatani, Satoshi ^a   Hashimura, Kazuhiko ^a   Kanzaki, Hideaki ^a   Komamura, Kazuo ^a   Asakura, Masanori ^a   Asanuma, Hiroshi ^a   Kitamura, Soichiro ^a   Tomoike, Hitonobu ^a   Kitakaze, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NITRATE; SPIRONOLACTONE; TEPRENONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GASTRITIS; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; FAMOTIDINE; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; PROSPECTIVE STUDIES; RECEPTORS, HISTAMINE H2; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33748942060     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.05.069     Document Type: Article

References (38)

1. Braunwald E., and Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 102 (2000) 14-23
2. Torre-Amione G. The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. Curr Opin Cardiol 14 (1999) 193-195
3. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 77 (1988) 721-730
4. Drexler H., and Hornig B. Importance of endothelial function in chronic heart failure. J Cardiovasc Pharmacol 27 (1996) S9-S12
5. Hough L.B. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 59 (2001) 415-419
6. Leurs R., Bakker R.A., Timmerman H., et al. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 4 (2005) 107-120
7. Gantz I., Schaffer M., DelValle J., et al. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci U S A 88 (1991) 429-433
8. Kim J., Washio T., Yamagishi M., et al. A novel data mining approach to the identification of effective drugs or combinations for targeted endpoints-application to chronic heart failure as a new form of evidence-based medicine. Cardiovasc Drugs Ther 18 (2004) 483-489
9. Matsuda N., Jesmin S., Takahashi Y., et al. Histamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans. J Pharmacol Exp Ther 309 (2004) 786-795
10. Hill S.J., Ganellin C.R., Timmerman H., et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49 (1997) 253-278
11. Eckel L., Gristwood R.W., Nawrath H., et al. Inotropic and electrophysiological effects of histamine on human ventricular heart muscle. J Physiol 330 (1982) 111-123
12. Du X.Y., Schoemaker R.G., Bos E., et al. Effects of histamine on porcine isolated myocardium: differentiation from effects on human tissue. J Cardiovasc Pharmacol 22 (1993) 468-473
13. Hattori Y. Cardiac histamine receptors: their pharmacological consequences and signal transduction pathways. Methods Find Exp Clin Pharmacol 21 (1999) 123-131
14. Kirch W., Halabi A., and Hinrichsen H. Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clin Pharmacol Ther 51 (1992) 325-333
15. Maronle G. The role of mast cells in cardiovascular disease. In: Matsumori A. (Ed). Cardiomyopathies in Heart Failure: Biomolecular, Infectious and Immune Mechanisms (2003), Kluwer Academic Publishers, Norwell, MA 185-228
16. Carlsson R., Dent J., Bolling-Sternevald E., et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 33 (1998) 1023-1029
17. Pollock M.L., Lowenthal D.T., Phillips M.I., and Staples E.D. Abnormal neuroendocrine responses during exercise in heart transplant recipients. Circulation 86 (1992) 1453-1463
18. Goldstein M., Vincent J.L., and Kahn R.J. Evaluation of cardiac function by echo-Doppler studies in critically ill patients. Intensive Care Med 14 (1988) 406-410
19. Dvorak A.M. Mast-cell degranulation in human hearts. N Engl J Med 315 (1986) 969-970
20. Marone G., de Crescenzo G., Adt M., Patella V., Arbustini E., and Genovese A. Immunological characterization and functional importance of human heart mast cells. Immunopharmacology 31 (1995) 1-18
21. Hara M., Ono K., Hwang M.W., et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 195 (2002) 375-381
22. Panizo A., Mindan F.J., Galindo M.F., Cenarruzabeitia E., Hernandez M., and Diez J. Are mast cells involved in hypertensive heart disease?. J Hypertens 13 (1995) 1201-1208
23. Patella V., Marino I., Arbustini E., et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 97 (1998) 971-978
24. Frangogiannis N.G., Perrard J.L., Mendoza L.H., et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 98 (1998) 687-698
25. Laine P., Kaartinen M., Penttila A., et al. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99 (1999) 361-369
26. Wolff A.A., and Levi R. Histamine and cardiac arrhythmias. Circ Res 58 (1986) 1-16
27. Bristow M.R., Ginsburg R., and Harrison D.C. Histamine and the human heart: the other receptor system. Am J Cardiol 49 (1982) 249-251
28. Hofstra C.L., Desai P.J., Thurmond R.L., et al. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 305 (2003) 1212-1221
29. Lohse M.J., Engelhardt S., and Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ Res 93 (2003) 896-906
30. Gespach C., Bouhours D., Bouhours J.F., et al. Histamine interaction on surface recognition sites of H2-type in parietal and non-parietal cells isolated from the guinea pig stomach. FEBS Lett 149 (1982) 85-90
31. Ottosson A., Jansen I., and Edvinsson L. Pharmacological characterization of histamine receptors in the human temporal artery. Br J Clin Pharmacol 27 (1989) 139-145
32. Al-Gadi M., and Hill S.J. The role of calcium in the cyclic AMP response to histamine in rabbit cerebral cortical slices. Br J Pharmacol 91 (1987) 213-222
33. Johnson C.L., Weinstein H., and Green J.P. Studies on histamine H2 receptors coupled to cardiac adenylate cyclase. Blockade by H2 and H1 receptor antagonists. Mol Pharmacol 16 (1979) 417-428
34. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
35. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
36. Ginsburg R., Bristow M.R., Davis K., et al. Quantitative pharmacologic responses of normal and atherosclerotic isolated human epicardial coronary arteries. Circulation 69 (1984) 430-440
37. Metra M., Nardi M., Giubbini R., et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24 (1994) 1678-1687
38. Lucas Jr. B.D., Williams M.A., Mohiuddin S.M., LaMadrid L.J., Schroeder L.J., and Hilleman D.E. Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure. Pharmacotherapy 18 (1998) 824-830